F/Prime Capital (Fidelity), Stanford University, and Chan-Zuckerberg Biohub biopharma, clinical genomics, and data platform spinnout focused on addressing large- scale cohort diversity and health equity in precision medicine. Founded and led by by world-renowned population geneticist and Stanford professor Carlos Bustamante, MS, PhD. Investors also include Digitalis, Helios, Keystone Group, Alexandria Ventures, HBM Genomics, AME Cloud, and Alix.

- Stealth / Seed - Combination siRNA (CNS) Therapeutics (Academic Lab Spinout)- mi:RNA Diagnostics / Series A - Veterinary Molecular Diagnostics- unPLUG Dining / Seed - AI-enabled restaurant technology platform- Stealth / Seed - CRISPR Therapeutics / Quantitative Drug Discovery Platform- Stealth / Series B - Cell Therapeutics and Manufacturing Platform- Stealth / Seed - Human and Planetary Health Data and Consumer Platform Technology

Specialist early- to growth stage Animal Health and Petcare venture firm. Focus Areas: Therapeutics | Diagnostics | Petcare | Veterinary Services | Consumer | Pet Food

Pioneering a novel portfolio of biotherapeutics for diseases of immunologic dysregulation in animals.

First-in-class next-generation sequencing (NGS) multi-cancer early detection (MCED) liquid biopsy platform for companion animals (veterinary medicine diagnostics). Founded and led by Dr. Daniel Grosu, former Chief Medical Officer of Illumina and Sequenom (acq. LabCorp). Investors included Longview (Crown), Declaration Partners, Torch Capital, Valor Equity Partners, and LabCorp.

Due diligence, business & financial analysis, investment memo development across Life Sciences and High Technology sectors.

U.S. Health system, Medical Group, Payor and Provider engagements spanning strategic planning, M&A, restructuring, and valuation advisory. Focus on health equity and value based care models.